Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus periprocedural tirofiban in high-risk NSTE-ACS undergoing PCI
ChiCTR-TRC-12002699Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tirofiban in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Major adverse cardiovascular events. Started Oct 2010; status: completed.
02
Drugs
tirofiban
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on ChiCTR-TRC-12002699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002699.